InsiderTrades.com logo

CYCC Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 51.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $83,430.00

Cyclacel Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclacel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclacel Pharmaceuticals Share Price & Price History

Current Price: $6.37
Price Change: +0.30 (1.20%)
As of 04/8/2026 01:00 AM ET

This chart shows the closing price history over time for CYCC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Cyclacel Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/30/2025David E LazarMajor ShareholderSell6,750$12.36$83,430.00155,838View SEC Filing Icon  
2/26/2025David E. LazarCEOSell810,953$7.20$5,838,861.60View SEC Filing Icon  
12/21/2023Paul McbarronInsiderBuy7$794.40$5,560.80139View SEC Filing Icon  
12/21/2023Spiro George RombotisCEOBuy25$794.40$19,860.00286View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

23.58% of Cyclacel Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYCC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclacel Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/15/2025Armistice Capital LLC1,269,485$0.35M0.0%+118.7%0.612%Search for SEC Filing on Google Icon
8/15/2024Armistice Capital LLC134,000$0.22M0.0%N/A9.178%Search for SEC Filing on Google Icon
5/10/2024Acadian Asset Management LLC14,285$29K0.0%-41.0%1.084%Search for SEC Filing on Google Icon
11/1/2022Kestra Advisory Services LLC23,000$34K0.0%N/A0.183%Search for SEC Filing on Google Icon
10/25/2022Raymond James Financial Services Advisors Inc.20,806$30K0.0%-32.5%0.166%Search for SEC Filing on Google Icon
10/18/2022McIlrath & Eck LLC26,342$38K0.0%N/A0.210%Search for SEC Filing on Google Icon
8/15/2022Sio Capital Management LLC454,355$0.49M0.2%+7.5%4.546%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC23,242$89K0.0%N/A0.233%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
Read More on Cyclacel Pharmaceuticals

Today's Range

Now: $6.37
Low: $6.37
High: $6.37

50 Day Range

MA: $7.23
Low: $6.36
High: $9.28

52 Week Range

Now: $6.37
Low: $3.08
High: $597.60

Volume

N/A

Average Volume

82,670 shs

Market Capitalization

$14.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.15

Who are the company insiders with the largest holdings of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' top insider investors include:
  1. David E Lazar (Major Shareholder)
  2. Eastern Capital Ltd (Major Shareholder)
  3. Spiro George Rombotis (CEO)
  4. Paul Mcbarron (Insider)
  5. David E Lazar (CEO)
  6. Kevin C Tang (Major Shareholder)
  7. Lloyd Sems (Director)
  8. Paul Mcbarron (CFO)
  9. Sam L Barker (Director)
  10. Spiro George Rombotis (Insider)
Learn More about top insider investors at Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals Active Insiders

Spiro George Rombotis
Spiro George Rombotis (Age 67)
CEO
Sam L Barker
Director